首页 国际期刊 医学期刊 期刊详情(非官网)
400-808-1701

Therapeutic Advances In Medical Oncology

Therapeutic Advances In Medical Oncology杂志,由SAGE Publications Inc.出版,于2009年创刊,Continuous publication,出版语言English,ISSN:1758-8340,E-ISSN:1758-8359。

投稿咨询
Therapeutic Advances In Medical Oncology
Therapeutic Advances In Medical Oncology
Therapeutic Advances In Medical Oncology
SCI SCIE

杂志介绍

JCR分区
Q2
中科院分区
2区
影响因子
4.1
CiteScore
6.2
期刊收录
SCI、SCIE

Therapeutic Advances In Medical Oncology(中文译名:《医学肿瘤学的治疗进展》),ISSN:1758-8340,EISSN:1758-8359,是SAGE Publications Inc.出版的国际性学术期刊,创刊于2009年,以Continuous publication形式稳定发行,2026年总发文量约267篇。该刊采用OA开放访问,学科归属为ONCOLOGY。该刊是医学、肿瘤学领域的国际权威刊物,已被SCI(科学引文索引)、SCIE(科学引文索引扩展版)等国际主流学术数据库收录。2026年期刊影响因子达4.1,2025年期刊CiteScore为6.2,2025年期刊自引率约2.4%,在中科院期刊分区体系中位列医学大类2区,在所属学科领域具备高学术影响力与国际认可度。Therapeutic Advances In Medical Oncology长期聚焦医学、肿瘤学及相关产业的技术应用前沿,平均审稿周期15 Weeks,审稿流程高效稳定。在稿件录用评判中,该刊将创新性与前沿性作为核心遴选标准,重点收录能够对医学、肿瘤学领域的落地与发展产生实质性推动价值的研究成果。

从全球发文格局来看,CHINA MAINLANDItaly、USA、England、Spain、GERMANY (FED REP GER)、France等为核心发文国家与地区;SUN YAT SEN UNIVERSITYSTATE KEY LAB ONCOLOGY SOUTH CHINA、UNICANCER、CHINESE ACADEMY OF MEDICAL SCIENCES - PEKING UNION MEDICAL COLLEGE、HARVARD UNIVERSITY、UNIVERSITY OF BOLOGNA、UNIVERSITY OF TEXAS SYSTEM等高校与科研机构是期刊的主要发文单位。

期刊评价

名词解释:

影响因子(Impact Factor, IF):指该期刊前两年发表的文章,在第三年的平均被引用次数。它反映了期刊的近期平均影响力和热度。

中科院分区:中科院分区表是国内主流的学术期刊分级评价工具,核心意义是建立跨学科可比的统一评价标尺,为职称评审、学位授予、科研立项等科研管理工作提供标准化量化依据,同时帮助科研人员筛选优质期刊、规避学术风险,适配国内本土化的科研评价需求。

期刊分区表

《新锐期刊分区表》(2026年3月发布)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
3区

期刊分区表(2025年3月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
3区

期刊分区表(2023年12月升级版)

大类学科 小类学科 Top期刊 综述期刊
医学
2区
ONCOLOGY 肿瘤学
3区

JCR分区

2025-2026年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 111 / 333

66.8

学科:ONCOLOGY SCIE Q2 142 / 333

57.51

2023-2024年最新版

按JCI指标学科分区 收录子集 分区 排名 百分位
学科:ONCOLOGY SCIE Q2 88 / 322

72.8

学科:ONCOLOGY SCIE Q2 113 / 322

65.06


中国学者近期发文

1
Low-level HBV viremia independently predicts poor outcomes in patients with intermediate-to-advanced HBV-related hepatocellular carcinoma receiving systemic therapy: a multicenter retrospective stud

Author:Lei, Jin; Ma, Huaxing; Chen, Xiong; Lin, Ling; Liang, Zhipeng; Ou, Guangling; Jin, Jiliang; Dai, Hongyuan; Zhang, Ya; Liu, Mei; Li, Haiyang; Lu, Yinying

Journal: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 2026; Vol. 18, Issue , pp. -. DOI: 10.1177/17588359261435330

2
Treatment patterns and clinical outcomes of neoadjuvant chemoimmunotherapy for patients with resected oesophageal squamous cell carcinoma: a Chinese multicentre retrospective stud

Author:Yu, Xiangyang; Zhu, Jianfei; Wang, Feng; Ma, Kai; Guo, Xiaotong; Zhang, Baihua; Wang, Lixu; Yu, Xin; Lin, Shengcheng; Ng, Calvin S. H.; Yang, Ran; He, Jie; Yu, Zhentao

Journal: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 2026; Vol. 18, Issue , pp. -. DOI: 10.1177/17588359261443147

3
S100A4 characterize antigen-presenting cancer-associated fibroblasts and predicts surgical outcomes in relapsed ovarian cance

Author:Maimaiti, Yilizhati; Chen, Yulian; Li, Longxia; Cai, Meichun; Li, Zeyun; Lin, Lifeng; Gao, Shangbing; Zhuang, Guanglei; Wu, Wei; Zang, Rongyu

Journal: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 2026; Vol. 18, Issue , pp. -. DOI: 10.1177/17588359261436959

4
A real-world study on the comparative effectiveness of first-line treatment regimens in advanced NSCLC patients with PACC mutation

Author:Liu, Dujiang; Li, Xinyue; Yin, Kailai; Lu, Yi; Han, Na; Xu, Yanjun

Journal: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 2026; Vol. 18, Issue , pp. -. DOI: 10.1177/17588359261442625

5
Comparative effectiveness of first-line taxane-platinum versus fluorouracil-platinum chemotherapy in advanced esophageal squamous cell carcinoma: a propensity score-matched real-world stud

Author:Ye, Sisi; Li, Chao; Liu, Rongrui; Zhao, Chuanhua; Li, Juan; Xu, Jianming

Journal: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 2026; Vol. 18, Issue , pp. -. DOI: 10.1177/17588359261436621

6
Anti-PD-1 matches interferon as adjuvant therapy for acral melanoma: a retrospective stud

Author:Du, Yu; Chen, Yu; Wang, Jiaxiang; Lin, Jing; Wei, Xiaoting; Gu, Junjie; Guo, Jun; Si, Lu; Mao, Lili

Journal: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 2026; Vol. 18, Issue , pp. -. DOI: 10.1177/17588359261436189

7
Integrating intracranial hypofractionated radiotherapy with immunotherapy for melanoma brain metastases: therapeutic impact and immune modulatio

Author:Lin, Jing; Zhang, Ting; Zeng, Yibin; Tang, Lirui; Cai, Jieyuan; Chen, Ling; Fang, Jiazhen; Chen, Yu; Li, Jinluan

Journal: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 2026; Vol. 18, Issue , pp. -. DOI: 10.1177/17588359261444616

8
The relationship between genetic mutations and organ metastasis in non-small cell lung cance

Author:Xue, Haiying; Chen, Yuzhu; Qi, Fei; Chen, Kaixuan; Liu, Xiaolin; Zhang, Muxin; Gao, Ziyuan; Cai, Shanshan; Gao, Tianbo; Zhang, Tongmei

Journal: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 2026; Vol. 18, Issue , pp. -. DOI: 10.1177/17588359261424770

9
The differences of pelvic lymph node metastasis between squamous cell carcinoma and adenocarcinoma in early-stage cervical cancer patients undergoing radical surgery and adjuvant radiotherapy: a large cohort stud

Author:Miao, Zheng; Yang, Xi-Lin; Zhu, Jia-Wei; Zhou, Yun-Can; Guan, Hui; Yan, Jun-Fang; Peng, Peng; Zhang, Fu-Quan

Journal: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 2026; Vol. 18, Issue , pp. -. DOI: 10.1177/17588359261425694

10
Fotemustine-containing chemotherapy suggests lower toxicity with comparable efficacy versus high-dose methotrexate-based regimens: a retrospective cohort analysi

Author:Zhang, Xudong; Zhao, Wanyue; Wang, Wenhua; Wu, Jingjing; Fan, Mengke; Ma, Shanshan; Dong, Meng; Zhu, Linan; Wu, Xiaolong; Feng, Xiaoyan; Li, Xin; Li, Ling; Sun, Zhenchang; Wang, Xinhua; Fu, Xiaorui; Li, Zhaoming; Yan, Jiaqin; Chang, Yu; Yu, Hui; Nan, Feifei; Zhou, Zhiyuan; Ding, Mengjie; Zhang, Jieming; Zhang, Lei; Zhang, Mingzhi

Journal: THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY. 2026; Vol. 18, Issue , pp. -. DOI: 10.1177/17588359261426830


在线咨询

Therapeutic Advances In Medical Oncology

国际简称:THER ADV MED ONCOL参考译名:医学肿瘤学的治疗进展

年发文量:267 CiteScore:6.2 是否预警:否 Gold OA文章占比:99.85% 研究类文章占比:76.40%

杂志社联系方式:SAGE PUBLICATIONS LTD, 1 OLIVERS YARD, 55 CITY ROAD, LONDON, ENGLAND, EC1Y 1SP

Therapeutic Advances In Medical Oncology